Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2][3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. [6] .

Boceprevir is used in combination with injectable peginterferon alfa (Pegasys®, Pegintron®) and ribavirin (Copegus®, Rebetol®) to treat chronic hepatitis C infection.

2023年8月23日 · Victrelis (boceprevir) is an antiviral medication used in combination with other medicines to treat chronic hepatitis C. Includes Victrelis side effects, interactions and indications.

VICTRELIS™ (boceprevir) is indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older)...

Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults who have...

Boceprevir is a man-made antiviral medication that targets hepatitis C virus (HCV). Similar drugs include simeprevir (Olysio) and telaprevir (Incivek). These drugs are called direct-acting antiviral agents because they act directly on hepatitis C virus.

Boceprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Boceprevir may not prevent the spread of hepatitis C to other people.

2022年1月26日 · Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that was used in combination with peginterferon and ribavirin in the treatment of chronic hepatitis C, genotype 1.

Boceprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Boceprevir may not prevent the spread of hepatitis C to other people.

Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).